SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Öhrfelt Annika 1973 ) srt2:(2015-2019);srt2:(2017)"

Sökning: WFRF:(Öhrfelt Annika 1973 ) > (2015-2019) > (2017)

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Sjödin, Simon, et al. (författare)
  • Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
  • 2017
  • Ingår i: Proteomics - Clinical Applications. - John Wiley and Sons Inc.. - 1862-8346. ; 11:11-12
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: Dysfunctional proteostasis, with decreased protein degradation and an accumulation of ubiquitin into aggregated protein inclusions, is a feature of neurodegenerative diseases. Identifying new potential biomarkers in cerebrospinal fluid (CSF) reflecting this process could contribute important information on pathophysiology. Experimental design: A developed method combining SPE and PRM-MS is employed to monitor the concentration of ubiquitin in CSF from subjects with Alzheimer's disease (AD), Parkinson's disease (PD), and progressive supranuclear palsy (PSP). Four independent cross-sectional studies are conducted, studies 1–4, including controls (n = 86) and participants with AD (n = 60), PD (n = 15), and PSP (n = 11). Results: The method shows a repeatability and intermediate precision not exceeding 6.1 and 7.9%, respectively. The determined LOD is 0.1 nm and the LOQ range between 0.625 and 80 nm. The CSF ubiquitin concentration is 1.2–1.5-fold higher in AD patients compared with controls in the three independent AD-control studies (Study 1, p < 0.001; Study 2, p < 0.001; and Study 3, p = 0.003). In the fourth study, there is no difference in PD or PSP, compared to controls. Conclusion and clinical relevance: CSF ubiquitin may reflect dysfunctional proteostasis in AD. The described method can be used for further exploration of ubiquitin as a potential biomarker in neurodegenerative diseases.
2.
  • Førland, Marthe Gurine, et al. (författare)
  • Validation of a new assay for α-synuclein detection in cerebrospinal fluid.
  • 2017
  • Ingår i: Clinical chemistry and laboratory medicine. - 1437-4331. ; 55:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Abnormal α-synuclein aggregation and deposition is the pathological hallmark of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), but is also found in Alzheimer disease (AD). Therefore, there is a gaining interest in α-synuclein in cerebrospinal fluid (CSF) as potential biomarker for these neurodegenerative diseases. To broaden the available choices of α-synuclein measurement in CSF, we developed and validated a new assay for detecting total α-synuclein.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2
 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy